Details for Patent: 5,428,062
✉ Email this page to a colleague
Title: | Prostaglandins E and anti ulcers containing same |
Abstract: | The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advatage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer. |
Inventor(s): | Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Kato; Ichie (Kawanishi, JP), Oda; Tomio (Sanda, JP) |
Assignee: | K.K. Ueno Seiyaku Oyo Kenkyujo (Osaka, JP) |
Filing Date: | Apr 28, 1993 |
Application Number: | 08/053,487 |
Claims: | 1. Prostaglandins E represented by a general formula: in which X represents: ##STR47## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydroxyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond. 2. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR48## in which X represents: ##STR49## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydroxyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond. 3. Prostaglandins E represented by a general formula: ##STR50## in which X represents: ##STR51## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkysilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom or a methyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond. 4. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR52## in which X represents: ##STR53## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkysilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom or a methyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond. 5. Prostaglandins E represented by a general formula: ##STR54## in which X represents: ##STR55## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkysilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom or a methyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, in which the C.sub.2 -C.sub.3 bond is a double bond. 6. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR56## in which X represents: ##STR57## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkysilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom or a methyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, in which the C.sub.2 -C.sub.3 bond is a double bond. 7. A method of treating an ulcer comprising administering to a patient in need of such treatment an anti-ulcer effective amount of a prostaglandin E represented by a general formula: ##STR58## in which X represents: ##STR59## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group; R.sub.2 represents: a hydrogen atom or a methyl group; R.sub.3 represents: a hydroxyl or hydroxymethyl group; R.sub.4 represents: a hydrogen atom, a methyl group or a hydroxyl group; R.sub.5 represents: a hydrogen atom or a methyl group; and R.sub.6 represents: a C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, in which the C.sub.2 -C.sub.3 bond is a single or a double bond; provided that when R.sub.4 and R.sub.5 are each hydrogen, R.sub.6 is a C.sub.5 -C.sub.9 alkyl group which may have a branch or a double bond, or a C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group. |